Will ARVN go up in the next week?

**ARVN's likelihood of an upward price movement in the next week is moderate**, considering the following factors:

1. **Current Price Trend**: ARVN is currently between narrow support and wide support levels, as well as between narrow and wide resistance levels. The stock is considered bearish, but the recent positive reaction to the CEO's retirement suggests that investor confidence is high.
2. **Forecast Price**: The forecast for ARVN shows a bullish outlook for the short term, with a mean forecast price of $7.62 on July 17, 2025, ranging from $7.46 to $7.7 over the next few days. This indicates a potential for price appreciation, but it also suggests that the stock may face some upward pressure in the near term.
3. **Market Sentiment**: Despite the CEO's retirement, which could have led to uncertainty, the market has responded positively, with the stock surging by 2.62% on the news of the CEO's retirement. This suggests that investor confidence is high, especially given the potential for vepdegestrant to become the first approved treatment for ESR1-mutant patients.
4. **Analyst Ratings**: Analysts have recently reaffirmed a Buy rating on ARVN, citing the potential of vepdegestrant and the company's undervaluation. This sentiment is reflected in the forecast performance, which shows an expected maximum gain of 16.79% with a potential maximum loss of -7.81%.

Considering these factors, ARVN has a moderate likelihood of an upward price movement in the next week. However, investors should be aware of potential volatility and the risks associated with the bearish trend. The forecast suggests that while there is potential for growth, there are also concerns about competitive pressures and the timeline for regulatory approvals.